loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of NOVOLOG reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    NOVOLOG

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 63,712Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 6Fiasp

    02 5NovoMix

    03 1NovoMix/NovoLog Mix

    04 5NovoRapid

    05 1NovoRapid/NovoLog

    06 2Novomix/Novolog Mix

    07 2Novorapid/Novolog

    08 5Ryzodeg

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : NovoRapid

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : NovoRapid

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 2,753

    2019 Revenue in Millions : 2,937

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Fiasp

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Fiasp

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 225

    2019 Revenue in Millions : 202

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : NovoMix

    Biphasic Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : NovoMix

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Biphasic Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 1,567

    2019 Revenue in Millions : 1,559

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Ryzodeg

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Ryzodeg

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 210

    2019 Revenue in Millions : 162

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : NovoMix

    Biphasic Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : NovoMix

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Biphasic Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 1,447

    2020 Revenue in Millions : 1,541

    Growth (%) : -1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : NovoRapid

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : NovoRapid

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 2,429

    2020 Revenue in Millions : 2,708

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Ryzodeg

    IInsulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Ryzodeg

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    IInsulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 261

    2020 Revenue in Millions : 207

    Growth (%) : 33

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Fiasp

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Fiasp

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 266

    2020 Revenue in Millions : 222

    Growth (%) : 26

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Fiasp

    Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Fiasp

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 292

    2021 Revenue in Millions : 266

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : NovoMix

    Biphasic Insulin Aspart

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : NovoMix

    Denmark
    arrow
    Discovery on Target
    Not Confirmed

    Novo Nordisk

    Biphasic Insulin Aspart

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 1,119

    2021 Revenue in Millions : 1,447

    Growth (%) : -23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF